IEU DMER

MRC IEU: Data Mining Epidemiological Relationships

Reducing drug development costs

A new animation

Overview This short animation explains how we use Mendelian randomization and colocalization to help prioritise drug targets. One of our aims in both programme 4 of the MRC IEU and the Integrative Cancer Epidemiology Programme is to integrate such prioritizations with other data to help inform drug development. Video  About the animation The animation is based on recent work by Dr Jie (Chris) Zheng, Vice-Chancellors Fellow based in programme 4 of the MRC IEU, who recently published an innovative Mendelian randomization and colocalization study of plasma protein levels in Nature Genetics, that demonstrated how genetic data can be used to support drug target prioritisation by identifying the causal effects of proteins on diseases.

Drug target prioritization using protein QTL

Overview An innovative genetic study of blood protein levels, led by researchers in the DMER programme at the MRC Integrative Epidemiology Unit (MRC-IEU) at the University of Bristol, has demonstrated how genetic data can be used to support drug target prioritisation by identifying the causal effects of proteins on diseases. Working in collaboration with pharmaceutical companies, Bristol researchers have developed a comprehensive analysis pipeline using genetic prediction of protein levels to prioritise drug targets, and have quantified the potential of this approach for reducing the failure rate of drug development.